LENZ (LENZ) Q4 2025: 45,000 Prescriptions Signal Early Momentum as Presbyopia Category Takes Shape

2026-03-24 | By EarningsIQ Research

LENZ’s first full quarter of commercial launch saw over 45,000 prescriptions filled and more than 10,000 eye care professionals engaged, indicating early traction in building a new presbyopia treatment category. Management is leaning into both physician and consumer education, expanding the sales force and optimizing direct-to-consumer campaigns to accelerate adoption. The company’s strong cash position enables continued investment, but the pace of new patient growth and refill behavior will be critical watchpoints as the market develops through 2026.

Summary

• Category Creation Dynamics: Early adoption patterns reflect the challenges and potential of building a new presbyopia treatment market.
• Physician Productivity Outpaces Prior Launches: Top prescribers are generating 40% more scripts per doctor versus historical benchmarks.
• Consumer and Field Expansion: Sales force and DTC investments are positioned to drive patient growth in the second half of 2026.

Performance Analysis

LENZ’s fourth quarter marked its first full period of commercial sales for VIZ, its presbyopia eye drop, with net product revenues of $1.6 million and over 20,000 paid prescriptions filled. Importantly, the company reported sales of over 45,000 boxes since launch, with more than 10,000 eye care professionals (ECPs) prescribing, a base that already exceeds comparable points in prior ophthalmology launches. The top 1,000 prescribers are writing 40% more scripts per doctor than seen in the VUITY launch, a prior benchmark product, suggesting strong early physician engagement among key adopters.

Operating expenses climbed to $40 million in Q4, up 43% sequentially, reflecting the ramp in commercial investment and the launch of a direct-to-consumer (DTC) campaign. Approximately 80% of SG&A spend was allocated to sales and marketing, a trend expected to persist as LENZ prioritizes category creation. R&D spend has dropped to negligible levels following product approval, with future focus squarely on commercial execution. Cash burn was $32 million for the quarter, but LENZ remains well-capitalized with $292 million on the balance sheet and no debt, supporting continued commercial investment.

• Physician Engagement Surpasses Peers: Over 10,000 ECPs have prescribed, exceeding benchmarks from recent launches such as MIEBO and XDEMVY at comparable stages.
• Sampling Strategy Drives Persistence: Early refill rates are encouraging, as patients who sample and purchase the product tend to continue therapy.
• Gross Margin Foundation: Management expects 90% gross margin on direct product sales, with net cash per unit in line with long-term targets.

While new patient starts are developing steadily rather than explosively, refill dynamics and physician adoption patterns signal a potentially durable, albeit gradual, build for the VIZ category.

Executive Commentary

Strategic Positioning

1. Physician Adoption as a Growth Lever

LENZ’s early commercial strategy centers on deepening engagement with ECPs, who are the gatekeepers for VIZ prescriptions. The company has expanded its field force from 88 to 117 representatives, increasing both breadth and frequency of physician touchpoints. Top prescribers are not only more productive than historical benchmarks, but the base is broadening as lower decile writers and new-to-category physicians begin to adopt the product. The emphasis is on integrating VIZ into routine eye exams to normalize its recommendation for a wide spectrum of presbyopia patients, not just early-stage cases.

2. Direct-to-Consumer (DTC) Campaigns Build Demand Engine

LENZ’s DTC campaign, featuring high-profile spokesperson Sarah Jessica Parker, is driving significant increases in website traffic—up to 10 times baseline during national activations. The company is testing linear TV in select high-adoption markets and investing in digital and influencer marketing to optimize reach and conversion. However, management cautions that DTC impact on prescription trends typically requires two or more quarters to materialize, given the multi-step consumer journey from awareness to physician visit to purchase.

3. Sampling and Patient Persistence as Key Differentiators

The company’s sampling-first approach is designed to foster self-selection and drive higher refill rates, building a more durable patient base compared to prior market entrants. Over 90% of new patients are estimated to have sampled the product before purchasing, and early data shows a shift from one-month to three-month prescriptions, indicating growing confidence and satisfaction among users. Management is tracking refill cohorts closely, with a focus on validating stickiness as a driver of long-term revenue.

4. Global Expansion in Motion

LENZ is advancing regulatory submissions for VIZ internationally, with filings underway in China, Southeast Asia, Europe, and the Middle East. The company expects multiple potential approvals in 2027, leveraging commercial partnerships to extend the product’s reach beyond the U.S. market. This global footprint offers optionality and long-term upside, though near-term results remain U.S.-centric.

Key Considerations

LENZ’s Q4 illustrates the realities of launching a new pharmaceutical category: strong early physician engagement, gradual patient ramp, and heavy up-front investment in commercial infrastructure and education. The company’s disciplined focus on physician integration, patient sampling, and consumer activation is designed to create a sticky, refill-driven business model, but execution risk remains as the market matures.

Key Considerations:

• Physician Messaging Evolution: Ongoing efforts to shift ECP perception from early presbyopes to the full spectrum of eligible patients are central to unlocking the broader market opportunity.
• Sales Force Expansion Impact: The increase from 88 to 117 reps aims to drive both new prescriber additions and higher call frequency, but will require careful productivity management to ensure ROI.
• DTC Optimization: Early digital and influencer metrics are promising, but true prescription lift will be a lagging indicator, requiring patience and ongoing creative/media refinement.
• Cash Burn and Capital Allocation: With $292 million in cash and a planned focus on commercial spend, LENZ has runway, but must demonstrate progress toward self-sustaining growth as OPEX remains elevated.

Risks

LENZ faces execution risk in scaling a new treatment category, including the challenge of converting high awareness and sampling into sustained patient growth and refill behavior. Physician inertia, competitive entrants, and the long lead time for DTC-driven prescriptions could delay the inflection in new patient starts. Elevated SG&A spend and a gradual revenue ramp will keep the company dependent on its cash reserves until the refill engine matures. Regulatory timelines for international expansion add further uncertainty.

Forward Outlook

For Q1 2026, LENZ expects:

• Continued growth in physician adoption and prescription volume as new reps come online
• Early signs of DTC campaign impact, with more meaningful prescription lift anticipated in the second half of 2026

For full-year 2026, management maintained guidance for:

• SG&A allocation of 75–80% to commercial activities, with R&D minimal
• Flat G&A spend and gross margin near 90% on product sales

Management highlighted that the primary focus remains on accelerating new patient adoption, expanding physician integration, and optimizing consumer marketing as the foundation for category growth.

• Sales force expansion and DTC campaigns are expected to drive a step-change in new patient starts in the latter half of the year
• International regulatory progress will continue, with multiple submissions targeted by year-end

Takeaways

LENZ’s early commercial execution is building a foundation for a potentially durable presbyopia treatment category, but the pace of patient ramp and refill persistence will be critical to long-term success.

• Early Physician Productivity: Top prescribers are driving outsized script volume, validating the product’s value proposition and informing broader field strategies.
• Consumer Activation Lag: DTC efforts are building awareness, but prescription conversion will take time, requiring ongoing investment and optimization.
• Refill Data as Key Proof Point: Investors should watch for concrete refill and persistence metrics in the second half of 2026 as the best indicator of category stickiness and revenue visibility.

Conclusion

LENZ’s first full quarter of VIZ commercialization demonstrates strong physician engagement and encouraging early refill signals, but underscores the long build required to establish a new treatment category. The company’s cash reserves and operational discipline provide runway, but sustained execution on physician integration and consumer activation will determine the ultimate scale and durability of the opportunity.

Industry Read-Through

LENZ’s launch highlights the operational and financial realities of building a new pharmaceutical category, particularly in eye care where physician education and patient persistence are critical. The measured rollout, sampling-first approach, and targeted DTC investments provide a playbook for other specialty pharma entrants seeking to create durable, refill-driven franchises. The lag between consumer awareness and prescription uptake is a cautionary signal for peers, while the productivity of top prescribers underscores the value of focused field execution. As the presbyopia segment matures, competitors will need to address similar challenges in physician integration, patient persistence, and capital allocation to achieve meaningful market penetration.

LENZ Healthcare Pharmaceuticals Commercialization Direct-to-consumer Presbyopia Physician adoption Refill persistence